Type 1 diabetes (T1D) is characterized by T cell-mediated destruction of the insulin-2 producing β cells of the pancreatic islets. Among the loci associated with T1D risk, those most 3 predisposing are found in the MHC region. HLA-B*39:06 is the most predisposing class I MHC 4 allele and is associated with an early age of onset. To establish an NOD mouse model for the 5 study of HLA-B*39:06, we expressed it in the absence of murine class I MHC. HLA-B*39:06 6 was able to mediate the development of CD8 T cells, support lymphocytic infiltration of the 7 islets, and confer T1D susceptibility. Because reduced thymic insulin expression is associated 8 with increased T1D risk in patients, we incorporated this in our model as well, finding that HLA-9
INTRODUCTION
Here we have developed HLA-B*39:06-transgenic NOD mouse models and have 1 demonstrated that HLA-B*39:06 is able to independently mediate the development of CD8 T 2 cells required for T1D onset. In the context of reduced thymic insulin expression, HLA-3 B*39:06-transgenic NOD mice develop T1D at an accelerated rate compared to mice with wild-4 type (WT) thymic insulin expression, despite normal blood insulin levels and no gross alterations 5 in lymphocyte composition or TCR V family usage. We propose that with a decrease in thymic 6 insulin expression, HLA-B*39:06 is less able to negatively select insulin-specific CD8 T cells 7 and, with the high concentration of insulin found in the islets, is able to present insulin epitopes 8 to escaped CD8 T cells. Thus, by generating HLA-B*39:06-transgenic NOD mice in the 9 presence of reduced thymic insulin expression, we show here the development of models that 10 will provide excellent tools for the examination of HLA-B*39:06's impact on T1D and for the 11 preclinical testing of HLA-B*39:06-targeted therapies. also crossed with male mice from NOD.β2m KO (37) or NOD.β2m KO .Ins2 KO strains (27) . To fix 17 the HLA-B*39:06 transgene to homozygosity, the resulting progeny were interbred as 18 appropriate to generate HLA-B*39:06 homozygous mice (HLA-B*39:06 Hom ) with the following 19 genotypes: NOD.HLA-B*39:06 Hom .β2m KO , NOD.HLA-B*39:06 Hom .β2m KO .Ins2 Het , and 20 NOD.HLA-B*39:06 Hom .β2m KO .Ins2 KO . As we and others have found that female NOD.β2m KO 21 mice breed poorly (38), we crossed male β2m KO mice with female β2m Het mice whenever 22 possible. The WT and KO β2m and WT and KO Ins2 alleles were identified by PCR using the 23 7 following primer pairs: β2m WT : 5′-GAAACCCCTCAAATTCAAGTATACTCA-3′ and 5′-1 GACGGTCTTGGGCTCGGCCATACT-3′; β2m KO : 5′-2 GAAACCCCTCAAATTCAAGTATACTCA-3′ and 5′-3 TCGAATTCGCCAATGACAAGACGCT-3′; Ins2 WT : 5′-GGCAGAGAGGAGGTGCTTTG-3′ 4 and 5′-AGAAAACCACCAGGGTAGTTAGC-3′; Ins2 KO : 5′-5 GGCAGAGAGGAGGTGCTTTG-3′ and 5′-ATTGACCGTAATGGGATAGG-3′. NOD.HLA-6 A*02:01 (HHD).β2m KO mice have been previously described (21). Mouse tails were numbed with ethyl chloride (Gebauer) and the tail tips were removed. System (Bio-Rad). Amplification was carried out as follows: initial denaturing at 94°C for 2 20 min, followed by 38 cycles of 20 s at 94°C, 15 s at 60°C and 10 s at 72°C. Copy numbers were 21 calculated using the 2 ΔΔCt method. Mice were monitored weekly from 4-30 wks for glucosuria using Diastix reagent strips 1 (Bayer). Mice were considered diabetic following two consecutive positive tests. The first 2 positive test was recorded as the date of diabetes onset. Pancreata were fixed in Bouin's solution, sectioned at three non-overlapping levels, and 6 stained with aldehyde fuchsin and hematoxylin and eosin. Islets were scored for insulitis by a 7 blinded observer as previously described (39): 0, no visible lesions; 1, peri-insular or non-8 invasive leukocytic aggregates; 2, <25% islet destruction; 3, 25-75% islet destruction; 4, >75% 9 islet destruction. A mean insulitis score was determined for each mouse by dividing the total 10 score for each pancreas by the total number of islets examined. Diabetic mice were assigned a 11 score of 4.
13
Blood collection and staining of peripheral blood leukocytes 14 Blood (10 µl) was collected from the mouse tail vein and added to 50 µl PBS (pH 7.2, 15 Gibco) with 1 mM EDTA (Sigma). Samples were mixed well and erythrocytes were lysed for 2-16 3 min with 200 µl ACK lysis buffer (Lonza). Plates were centrifuged at 700xg for 3 min and 17 ACK lysis was repeated. Following centrifugation, samples were washed twice with PBS 18 containing 1% FBS (HyClone) and 0.1% (w/v) sodium azide. All subsequent washes and 19 dilutions were performed using this buffer. Cells were stained with Fc Block (BD Biosciences), Blood (20-40 µl) was collected from the mouse tail vein and allowed to clot at room 4 temperature for 1 h. Samples were centrifuged for 15 min at 960xg at 4°C. Serum was stored in 5 aliquots at -20°C. Blood insulin levels were measured using the Mouse Ultrasensitive Insulin 6 ELISA (ALPCO). Absorbance of each well at 405 nm was detected using an Emax precision 7 microplate reader (Molecular Devices) and the results were analyzed using GraphPad Prism 7 8 software. Mice were euthanized using CO 2 asphyxiation, followed by cervical dislocation. Spleens 12 were harvested and placed in ice-cold RPMI (Gibco) supplemented with 10% FBS, 1% sodium 13 pyruvate (Gibco), 1% non-essential amino acids (Gibco), 50 U/ml penicillin and 50 µg/ml 14 streptomycin (Gibco). Spleens were crushed, passed through a 40-µm cell strainer and washed 15 with RPMI. Samples were centrifuged at 486xg for 5 min. Erythrocytes were lysed in ACK 16 lysis buffer (Lonza) for 4 min at room temperature and washed with RPMI. The resultant cells 17 were centrifuged and washed twice with PBS. Prior to the final wash, samples were passed 18 through a 40-µm cell strainer. Cells were counted and suspended in PBS. Samples prepared in 19 the above manner were added to a V-bottomed plate and centrifuged at 486xg for 5 min. To begin to study the association of HLA-B*39:06 with T1D, we first developed 3 NOD.HLA-B*39:06 mice using a monochain HLA-B*39:06 construct. We tracked these mice 4 for susceptibility to disease to ensure that the integration of HLA-B*39:06 did not interfere with 5 T1D development. We found no decrease in disease susceptibility compared to non-transgenic 6 littermates in either females ( Fig. 1A) or males (Fig. 1B) . The earliest age of onset among 7 female mice was 14 wks, with 82% diabetic by 30 wks. In males, the earliest age of onset was at 8 13 wks, though as expected, incidence was reduced compared to females, with only 57% 9 converting to disease by 30 wks of age. Because females were more susceptible to disease than 10 males, we used female mice for our subsequent experiments. with low class I MHC levels, with an average MFI of 607, suggesting that the mice with 1 increased human class I MHC levels were HLA-B*39:06 Hom . We used real-time PCR for the 2 HLA-B*39:06 transgene to ensure that the high expressers were indeed homozygous for HLA-3 B*39:06 ( Fig. 2B ). We found that the average copy number of the low expressers was 1.6. This NOD.β 2 m KO mice, and the previously characterized NOD.HLA-A*02:01.β2m KO strain (21), 20 were also examined. As expected, only NOD splenocytes showed expression of murine class I 21 MHC (Fig. 3A) . The absence of murine class I MHC in NOD.β2m KO mice results in a lack of 22 CD8 T cells (Fig. 3B, 3C ), as reported previously (37). However, we observed a partial 23 13 restoration of CD8 T cell development in the NOD.HLA-B*39:06.β2m KO strain (Fig. 3B, 3C ), 1 demonstrating that HLA-B*39:06 is indeed able to mediate CD8 T cell development. We next examined the ability of HLA-B*39:06 to mediate the development of T1D. 5 NOD.β2m KO mice are protected from T1D because they lack CD8 T cells (37, 40-42). However, 6 homozygous expression of HLA-B*39:06 in NOD.β2m KO mice partially restored a disease 7 phenotype (Fig. 4A) , with the earliest age of onset at 20 wks and with 17% of NOD.HLA-8 B*39:06.β2m KO mice diabetic at 40 wks. We therefore show here for the first time that HLA-9 B*39:06 is able to independently lead to the development of T1D in mice. As previously 10 reported (21), homozygous expression of HLA-A*02:01 (HHD) also allowed for partial 11 restoration of disease susceptibility (Fig. 4A ). NOD.HLA-A*02:01.β2m KO mice had their 12 earliest age of onset at 10 wks of age, with 33% diabetic at 40 wks (Fig. 4A ). While the age of 13 onset in the HLA-B*39:06 mice was later than that seen in HLA-A*02:01 mice, the two 14 incidence curves were statistically indistinguishable (p = 0.17), and examination of insulitis in n-15 diabetic mice of each strain revealed similar amounts of islet infiltration (p = 0.15) ( Fig. 4B ). As little (28, 32) to no (33, 34) Ins1 expression occurs in the thymus, NOD.Ins2 KO mice 1 are characterized by greatly diminished thymic insulin expression (31). They display accelerated 2 T1D onset, increased insulitis, increased T cell reactivity to insulin, and impaired tolerance to 3 insulin compared to WT littermates (29-31). The impact of Ins2 deficiency on disease is 4 dependent on the genetic context, as NOD.HLA-A*02:01.β2m KO .Ins2 KO mice have a faster 5 disease onset than NOD.Ins2 KO mice (43), indicating that the effects of multiple risk alleles can 6 combine to increase risk. We find that, in conjunction with HLA-B*39:06, Ins2 deficiency leads 7 to a rapid onset of disease ( Fig. 5A, 5B ), demonstrating the importance of examining T1D in the 8 context of multiple risk factors. Female NOD.HLA-B*39:06.β2m KO mice had an earliest age of 9 onset of 25 wks, with 58% diabetic at 30 wks. In contrast, NOD.HLA-B*39:06.β2m KO .Ins2 KO 10 mice had an earliest age of onset of 12 wks, with 100% of this strain being diabetic by 16 wks.
11
We have previously noted that Ins2 Het NOD mice exhibit a modest decrease in thymic insulin 12 expression compared to WT NOD mice (27) . Comparison of incidence curves (Fig. 5A ) and age 13 at onset (Fig. 5B) CD4 T cells relative to NOD mice (21, 23). Given their similar background, we compared our 1 three NOD.HLA-B*39:06.β2m KO strains to age-matched NOD.HLA-A*02:01.β2m KO mice. We 2 found no significant changes in percentage in any of the splenocyte subsets examined (Fig. 6B ).
3
The percent of CD8 T cells found in the spleens of HLA-B*39:06 mice was consistent with that 4 found in blood (Fig. 2C) . Furthermore, the percentage of CD4 + CD25 + T cells was consistent 5 across all groups, suggesting that the change seen in disease susceptibility was not due to a 6 differing proportion of largely regulatory T cells. Together, these data suggest that the increase 7 in disease incidence seen in the NOD.HLA-B*39:06.β2m KO .Ins2 KO mice was not due to gross 8 changes in lymphocyte composition compared to the other groups examined. of anti-mouse TCR V antibodies. Separate examination of CD8 and CD4 T cells revealed no 15 significant differences in TCR V usage between these two strains of mice ( Fig. 7A, 7B) . When 16 the CD4 + CD25 + (largely regulatory) T cell population was examined individually, the Ins2 KO 17 mice showed a small but significant increase in the use of TCR V8.1/2 when compared to 18 Ins2 WT mice, but no other changes were noted (Fig. 7C ).
19
The availability of both NOD.HLA-B*39:06.β2m KO and NOD.HLA-A*02:01.β2m KO 20 mice presented a unique opportunity to examine the influence of HLA transgene identity on TCR 21 V usage. Examination of CD8 T cells revealed significant differences in usage of V2, V6,
22
V8.1/2, and V11 (Fig. 7A ). There were no differences in the usage of these TCR V families 23 when CD4 T cell populations were studied (Fig. 7B, 7C) , indicating that the presence of HLA- Because of the compensatory changes observed in pancreatic Ins gene expression when 5 the total number of Ins genes is reduced from four to two (28), we considered it unlikely that the 6 earlier age of disease onset seen in the NOD.HLA-B*39:06 Hom .β2m KO .Ins2 KO mice was due to 7 insufficient pancreatic insulin expression. To confirm this, we measured blood insulin levels in 8 young mice (5-6.5 wks old), well prior to disease onset (Fig. 8 ). We found that the level of 9 insulin expression was statistically indistinguishable between NOD.HLA-B*39:06 Hom .β2m KO 10 mice and their Ins2 Het and Ins2 KO counterparts, with an average concentration of 0.8 ng/ml, 11 consistent with previous reports for other mouse strains (44). This supports the notion that the 12 changes in disease onset are due to diminished immunological tolerance to insulin (30, 31) and 13 not to an inherently decreased ability to produce insulin.
DISCUSSION 1
Multiple loci are associated with T1D risk, including a number of class I and class II 2 MHC alleles (4). Among these, HLA-B*39:06 is not only the most predisposing class I HLA 3 allele in T1D patients (7, 9) , but also leads to an earlier age of disease onset (11). However, due 4 to the rarity of this allele among the populations studied thus far, investigation of the direct 5 impact of HLA-B*39:06 on T1D pathogenesis has not been possible (6, 7). It is important to 6 note that HLA-B*39:06 is more common among Latin American populations with allele 7 frequencies of 0.03 among Mexican Americans, 0.02-0.06 among Hispanic Americans, and 0.01-8 0.09 among Mexicans (12). The Venezuela Perja Mountain Bari population has an allele 9 frequency of 0.24. While T1D is relatively rare within Latin American countries, incidence is 10 rising worldwide and new patients from these populations can be expected (14, 15) . Similarly, 11 patients carrying this genetic variant can increasingly be found in countries where T1D incidence 12 is highest (45). While genetic background is important, environment is as well; when individuals 13 from areas with low T1D incidence move to areas with high incidence, they assume some of the 14 risk of their new environment (46, 47) . Therefore inclusion of HLA-B*39:06-positive patients in 15 treatment studies is essential. As such, the development of a mouse model for the study of HLA-16 B*39:06 is important as this resource can provide a useful preclinical tool for the testing of 17 HLA-B*39:06-directed treatments in the absence of sufficiently powered patient studies. 18 We have previously used an NOD.β2m KO -based model to study the contribution of 19 HLA-A*02:01 to T1D development (21). In the current study, we found that NOD.HLA-20 B*39:06 Hom .β2m KO mice develop similar amounts of CD8 T cells as their HLA-A*02:01-21 transgenic counterparts (Fig. 3B, 3C ), suggesting that HLA-B*39:06 is as efficient at leading to 22 CD8 T cell development as the more well-studied HLA-A*02:01. Indeed, we show here for the 23 18 first time that HLA-B*39:06 can directly mediate T1D in an NOD.β2m KO model (Fig. 4A, 5A ). 1 However, unlike HLA-A*02:01 (21, 48) , when expressed in the presence of the NOD class I 2 MHC alleles H2-D b and H2-K d , HLA-B*39:06 did not accelerate disease (Fig. 1 ). While this 3 may be due to strain-specific differences (e.g., transgene integration site), it also may speak to 4 the importance of other aspects of the genetic environment which are known to be important for 5 HLA-B*39:06-related susceptibility in humans. HLA-B*39:06 has been found to exert its effect 6 on T1D risk in patients with specific class II MHC haplotypes, namely HLA-DR8/DQ4 (6, 49).
7
Depending on the population studied, these class II MHCs may be independently predisposing, 8 in which case HLA-B*39:06 accelerates disease progression, or may have a neutral impact on 9 T1D, in which case HLA-B*39:06 lends risk to such patients. It has been well established that 10 H2-A g7 , the NOD class II MHC, bears great similarity to the human T1D-associated HLA-DQ8 11 (18). HLA-DR8, part of a haplotype associated with HLA-B*39:06, has similar peptide binding 12 characteristics to both H2-A g7 and HLA-DQ8 (50). While HLA-DR8 has been hypothesized to 13 be the T1D-causative allele in the HLA-DR8/DQ4 haplotype, other evidence suggests that HLA-14 DQ4 is associated with risk of greater disease progression (51) (52) (53) . Given that genetic context is 15 important for the association between HLA-B*39:06 and T1D risk, the lack of a class II MHC 16 molecule similar to HLA-DQ4 in the NOD mouse model may explain why similar diabetes 17 incidence curves were observed for NOD and NOD.HLA-B*39:06 mice (Fig. 1) . However, 18 despite potentially not having an ideal genetic environment, HLA-B*39:06 is still able to 19 mediate disease and islet infiltration, as confirmed by our findings in the NOD.HLA-20 B*39:06.2m KO strain (Fig. 4A, 4B, 4D, 5A ).
21
To more accurately model the genetic background of patients with T1D, we incorporated 22 reduced thymic insulin expression into the NOD.HLA-B*39:06.β2m KO model. We found that 23 19 NOD.HLA-B*39:06.β2m KO .Ins2 KO mice are susceptible to disease at a younger age compared to 1 their Ins2 WT counterparts (Fig. 5 ). Based on our findings that the gross lymphocyte populations 2 (Fig. 6B ), TCR V usage (Fig. 7) , and blood insulin levels (Fig. 8) do not differ dramatically 3 between these strains, the most likely explanation for the earlier age of onset in the context of 4 reduced insulin expression is a decrease in insulin tolerance (30, 31) . CD8 T cells are necessary 5 for the development of T1D (2, 37, (40) (41) (42) . As the expression of HLA-B*39:06 restores T1D 6 susceptibility to NOD.β2m KO mice (Fig. 4A, 5A) and is enhanced in the Ins2 KO mice (Fig. 5A) , it 7 is likely that reduced thymic insulin expression results in an increase in CD8 T cell reactivity 8 towards insulin. Increased CD4 T cell reactivity to insulin could also be a contributing factor. 9 We propose that an increased HLA-B*39:06-restricted reactivity to insulin may also contribute 10 to the earlier age of onset seen in HLA-B*39:06-positive patients. These points will be clarified 11 by future investigations.
12
The NOD.HLA-B*39:06.β2m KO model can be used in a variety of ways to probe the 13 influence of HLA-B*39:06 on T1D susceptibility. As we have successfully done for HLA-14 A*02:01 (21, 22, 29) , the model will allow us to identify the beta cell peptides recognized by 15 HLA-B*39:06-restricted T cells without the potentially confounding presence of murine class I 16 MHC molecules. That the peptide-binding motif for HLA-B*39:06 has recently been identified 17 may simplify the identification of HLA-B*39:06-restricted epitopes (54, 55). We have 18 previously identified HLA-A*02:01-restricted epitopes in an NOD.β2m 22, 19 29); these epitopes were the same or similar to those found in human T1D patients expressing 20 this class I variant (21, 23) . Thus the use of the NOD.HLA-B*39:06.β2m KO models could 21 provide a direct translational impact. Identification of HLA-B*39:06-restricted epitopes can 22 allow for their use in epitope-directed therapies; these are an attractive option as they can allow 23 20 for treatments targeted at specific epitopes without the risk of off-site effects. Furthermore, 1 knowledge of targeted epitopes allows for the tracking of response to therapy, e.g., through the 2 use of peptide-MHC tetramers. Such therapies require preclinical testing, representing another 3 future use of the NOD.HLA-B*39:06.β2m KO models. 4 Finally, it is important to appreciate that not all HLA class I molecules influence T1D in 5 the same way or to the same degree when expressed in NOD mouse models. For example, when 6 expressed along with H2-D b and H2-K d in NOD mice, HLA-A*02:01 accelerates disease onset 7 (21, 48), HLA-A*11:01 (56) and HLA-B*39:06 ( Fig. 1 ) have no effect, and HLA-B*27 is 8 protective (48). When we compared the TCR V usage among CD8 T cells in mice transgenic 9 for either HLA-A*02:01 or HLA-B*39:06 and lacking murine class I MHC molecules (Fig. 7A) , 10 we found that four TCR V families were differentially expressed. This was initially a 11 surprising finding, as until recently it was not generally thought that a given TCR V family had 12 any preference for a particular MHC allele (57). Recently, however, usage of TCR V (and V) 13 genes has been found to be associated with MHC genotype in humans, leading to the proposal 14 that different TCR V gene products may indeed have a bias toward particular MHC alleles (58).
15
Our results using the NOD.HLA-B*39:06.β2m KO and NOD.HLA-A*02:01.β2m KO strains (Fig. 16 7A) support this view and represent a valuable system to explore this phenomenon further.
17
Differences in TCR repertoire could help to explain the differential T1D susceptibility observed 18 not only in NOD mice transgenic for different HLA class I alleles, but, more importantly, in 19 humans as well.
20
In sum, we have established that HLA-B*39:06 can directly mediate T1D in the NOD 21 mouse model, confirming the results seen in multiple genome-wide association studies (5, 7).
22
We have furthermore developed models for HLA-B*39:06 in a genetic context more relevant to 23 21 human disease by incorporating reduced thymic insulin expression. These models will allow a 1 detailed investigation of the influence of HLA-B*39:06 on T1D development. represents an individual mouse. Lines denote mean ± SEM (p = 0.029, Mann-Whitney). (5-6.5 wks old) having the indicated Ins2 genotypes (Ins2 WT , n = 9; Ins2 Het , n = 14; Ins2 KO , n = 11 6) in the morning, and insulin levels were measured by ELISA. Each circle represents an 12 individual mouse. Lines denote mean ± SEM; p values are indicated (Mann-Whitney). Ins2 WT vs Ins2 het , p = 0.14 Ins2 WT vs Ins2 KO , p = 0.0013 Ins2 het vs Ins2 KO C p = 0.016 p = 0.017 p = 0.015 p = 0.027 p = 0.021 p = 0.009 Figure 8 NOD.HLA-B*39:06.b2m KO p = 0.88 p = 0.95
